What is an example of a first-line contraceptive Oral Contraceptive Pill (OCP)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

First-Line Contraceptive Oral Contraceptive Pills

Combined oral contraceptive pills (COCs) containing ethinyl estradiol 35 μg or less with levonorgestrel or norethindrone are considered first-line OCPs due to their effectiveness, relatively low risk of venous thromboembolism, and availability on prescription benefits programs. 1

Recommended First-Line OCPs

Low-Dose Combined Hormonal Contraceptives

  • Monophasic pills containing ethinyl estradiol 20-35 μg combined with a first or second generation progestin:
    • Ethinyl estradiol 20 μg/levonorgestrel 100 μg (low-dose option)
    • Ethinyl estradiol 30-35 μg/levonorgestrel or norethindrone

Effectiveness

  • First-line COCs have a typical-use failure rate of 5-9% but perfect-use failure rates as low as 0.1% 2, 3
  • Ethinyl estradiol/levonorgestrel 20 μg/100 μg has demonstrated a Pearl index of 0.88 pregnancies per 100 woman-years 4

Rationale for First-Line Selection

Safety Profile

  • First and second generation progestins (levonorgestrel, norethindrone) combined with low-dose ethinyl estradiol (≤35 μg) have the most favorable risk profile among combined hormonal methods 5
  • These formulations have a relatively lower risk of venous thromboembolism compared to newer generation progestins 5
    • Baseline VTE risk in non-users: 1 per 10,000 woman-years
    • Risk with COCs: 3-4 per 10,000 woman-years 6

Blood Pressure Considerations

  • Low-dose ethinyl estradiol formulations have less impact on blood pressure than higher-dose options 5
  • Studies comparing BP among individuals taking COCs with varying doses of first, second, and third generation progestins have not observed significant differences in BP elevations between groups 5

Newer Options to Consider

  • Drospirenone-containing pills (fourth generation progestin) may be beneficial for patients with hypertension concerns:
    • Demonstrated decreases in systolic blood pressure due to anti-mineralocorticoid effects 5
    • However, these are not considered first-line due to higher VTE risk compared to levonorgestrel-containing pills

Important Contraindications and Precautions

Absolute Contraindications

  • History of venous thromboembolism or arterial thrombotic disease
  • Breast or endometrial carcinoma
  • Undiagnosed abnormal genital bleeding
  • Severe hypertension
  • Diabetes with vascular involvement
  • Migraine with aura
  • Liver tumors
  • Age ≥35 years who smoke 6

Drug Interactions

  • Effectiveness may be reduced when used with:
    • Anticonvulsants
    • Some antimicrobials
    • HIV protease inhibitors
    • St. John's wort 5
  • Ritonavir-boosted protease inhibitors, nevirapine, and efavirenz can reduce hormonal levels, potentially decreasing contraceptive effectiveness 5

Clinical Pearls

  • Before prescribing, obtain thorough personal and family history of thrombotic events, measure blood pressure, screen for migraine with aura, assess for liver disease, and consider age and smoking status 6
  • For patients with higher BMI, consider higher estrogen doses or alternative methods as effectiveness may be reduced 6
  • Progestin-only pills (POPs) are an alternative for patients with contraindications to estrogen-containing methods, with perfect-use failure rates of 0.5% 2
  • Extended-cycle regimens (fewer or no inactive pills) may be beneficial for conditions like anemia, severe dysmenorrhea, endometriosis, and migraines without aura 6

Remember that while these first-line options are recommended based on safety and effectiveness, individual factors including medical history, risk factors, and preferences should guide the final selection.

References

Research

Choosing a combined oral contraceptive pill.

Australian prescriber, 2015

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Emergency Contraception Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.